Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634257 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL1814134 | 0.87 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL5747928 | 0.87 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL1217601 | 0.87 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL1218640 | 0.87 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL5838814 | 0.77 | CYP3A4 (0.34) | CYP3A4CYP2C9 | |
| SCHEMBL5840352 | 0.76 | CYP3A4 (0.32) | CYP3A4CYP2C9 | |
| SCHEMBL4880229 | 0.74 | CYP3A4 (0.37) | CYP3A4CYP2C9 | |
| SCHEMBL5838692 | 0.73 | CYP3A4 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL5839023 | 0.73 | CYP3A4 (0.35) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971922-B1 | TETRAHYDROPYRIDO COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-04-28 | — | — | EP | claimed |
| US-6197783-B1 | THERAPY FOR GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-06 | — | — | US | claimed |
| EP-0971922-A1 | TETRAHYDROPYRIDO COMPOUNDS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-01-19 | — | — | EP | claimed |
| WO-1998042707-A1 | TETRAHYDROPYRIDO COMPOUNDS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-10-01 | — | — | WO | claimed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | EDUSA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | EDUSA PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1663313-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005021040-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-0971922-B1 | TETRAHYDROPYRIDO COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-6197783-B1 | THERAPY FOR GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
| EP-0971922-A1 | TETRAHYDROPYRIDO COMPOUNDS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042707-A1 | TETRAHYDROPYRIDO COMPOUNDS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP3A4 1306/4885CYP2C9 1083/4885 |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP3A4 1306/4885CYP2C9 1083/4885 |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | HTR3A, HTR3D, HTR3B | CYP3A4 2764/4885CYP2C9 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.